Objective To compare the influence of hypoxia inducible factor prolylhydroxylaseinhibitors and recombinant human erythropoietin(rHuEPO)on cardiovascular indicators and cardiovascular and cerebrovascular complications in renal anemia patients undergoing dialysis.Method 53 patients who were treated with Roxadustat via oral administration for renal anemia in Beijing Luhe Hospital Capital Medical University from January 1,2022 to December 31,2022 as Roxadustat group were retrospectively analyzed.Patients who were treated with rHuEPO via subcutaneous injection were randomly enrolled in according toa ratio of 1:1 as rHuEPO group.The hemoglobin,blood pressure,cardiovascular indexes,cardio-cerebrovascular complications were compared between the two groups before and after 12 monthstreatment,and cerebrovascular complications were compared during 18 months of treatment.Results There were no significant differences in baseline clinical data and laboratory values between the twogroups(P＞0.05).After 12 months of follow-up,there was no statistical difference in Hb levels between the two groups after follow-up(P＞0.05),andHb in both groups was significantly increased compared with the baseline(P＜0.05).After 12 months of treatment,the proportion of nocturnal hypertension in Roxadustat group was lower than that in control group,and left ventricular ejection fraction(LVEF)was higher than that in control group,the difference was statistically significant(P＜0.05).Compared with baseline,after 12 months of treatment,the proportion of nocturnal hypertension,SBP and DBP increased in the control group,and LVEF and albumin increased in both groups,the difference was statistically significant(P＜0.05).At 18 months follow-up,the rate of heart failure in the control group was higher than that in the Roxadustatgroup(x2=1.940,P=0.010).Multivariate Cox regression analysis showed that use of rHuEPO was an independent risk factor for cardiovascular and cerebrovascular complications in dialysis patients(HR 2.22,95％ CI 1.13～4.33,P=0.020).Conclusion Compared with rHuEPO,Roxadustat has less effect on blood pressure and cardiovascular markers,improves LVEF,and reduces the risk of elevated blood pressure and cardiovascular complications in dialysis patients.
hypoxia inducible factor prolylhydroxylase inhibitorsrecombinant human erythropoietindialysis for uremiacardiovascular and cerebrovascular complications
国家科技期刊平台
NSTL
万方数据
